Checkpoint Therapeutics Inc (NASDAQ: CKPT) is 10.31% higher on its value in year-to-date trading and has touched a low of $1.38 and a high of $4.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CKPT stock was last observed hovering at around $3.73 in the last trading session, with the day’s loss setting it -0.2%.
Currently trading at $3.53, the stock is 13.14% and 0.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing -5.36% at the moment leaves the stock 34.10% off its SMA200. CKPT registered 90.81% gain for a year compared to 6-month gain of 57.59%. The firm has a 50-day simple moving average (SMA 50) of $3.5126 and a 200-day simple moving average (SMA200) of $2.621975.
The stock witnessed a -3.55% loss in the last 1 month and extending the period to 3 months gives it a 1.15%, and is 24.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.90% over the week and 7.27% over the month.
Checkpoint Therapeutics Inc (CKPT) has around 23 employees, a market worth around $172.38M and $0.05M in sales. Profit margin for the company is -98868.09%. Distance from 52-week low is 155.80% and -21.56% from its 52-week high.
The EPS is expected to grow by 72.34% this year
50.0 institutions hold shares in Checkpoint Therapeutics Inc (CKPT), with institutional investors hold 16.47% of the company’s shares. The shares outstanding are 45.10M, and float is at 35.85M with Short Float at 22.13%. Institutions hold 13.91% of the Float.
Checkpoint Therapeutics Inc (CKPT) Insider Activity
The most recent transaction is an insider sale by Oliviero James F III, the company’s CEO, President and Director. SEC filings show that Oliviero James F III sold 602,167 shares of the company’s common stock on Dec 18 ’24 at a price of $3.87 per share for a total of $2.33 million. Following the sale, the insider now owns 3.41 million shares.
Checkpoint Therapeutics Inc disclosed in a document filed with the SEC on Dec 19 ’24 that Oliviero James F III (CEO, President and Director) sold a total of 220,230 shares of the company’s common stock. The trade occurred on Dec 19 ’24 and was made at $3.38 per share for $0.74 million. Following the transaction, the insider now directly holds 3.19 million shares of the CKPT stock.
Still, SEC filings show that on Dec 18 ’24, GRAY WILLIAM GARRETT (Chief Financial Officer) disposed off 268,432 shares at an average price of $4.01 for $1.08 million. The insider now directly holds 1,032,754 shares of Checkpoint Therapeutics Inc (CKPT).
